Eyepoint Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Eyepoint Inc (EYPT) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Eyepoint Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 3M vs 18,503M combined for its competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-27.3% annualized vs trailing 12 months), vs accelerating (+2.0%) for its tracked peer group.
- Growth: Eyepoint Inc generated -90.5% revenue growth year over year in Q2 2026, vs 18.5% for its competitors combined.
- Profitability: Its -18,633.1% net margin compares with 23.1% for the peer group.
- Scale: Eyepoint Inc ranks #21 of 32 companies by market capitalization in the Laboratory Analytical Instruments industry, holding 0.0% of industry market cap.
- Peer revenue share: Eyepoint Inc accounted for 0.0% of combined revenue among its tracked peer group, down from 0.1% a year earlier.
- Peer differentiation: Revenue per employee of $0.01M compares with $1.03M for the peer group (0.0x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
EYPT Sales vs. its Competitors, Q2 2026
Eyepoint Inc reported revenue contraction of 90.49 % year on year in Q2 2026, below its competitors' combined revenue growth of 18.47 %.
With a net margin of -18,633.14 %, Eyepoint Inc reported lower profitability than its competitors (23.09 %).
Eyepoint Inc generated 0.01 % of the combined sales of its peer group, down from 0.13 % a year earlier.
API endpoints for this dataset
Eyepoint Inc vs. its Competitors, Q2 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Eyepoint Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Eyepoint Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Eyepoint Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (10) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Eyepoint Inc's competitor groups requires a Commercial License.
For context: the Laboratory Analytical Instruments industry grew revenue 13.0% year over year, combined, vs -90.5% for Eyepoint Inc. Eyepoint Inc's share of combined industry revenue moved from 0.06% to 0.00%, a loss of 0.05 percentage points.
Eyepoint Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Eyepoint Inc | No | No | No | Yes |
| Competitors combined (13) | ||||
| High-Confidence Competitors (4) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
EYPT Stock Performance relative to its Competitors
EYPT Stock Performance relative to High-Confidence Competitors
EYPT Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Glaukos Corp | 282.9% | Outperformed |
| 2 | Regeneron Pharmaceuticals Inc | 282.9% | Outperformed |
| 3 | Viridian Therapeutics Inc | 282.9% | Outperformed |
| 4 | Tarsus Pharmaceuticals Inc | 282.9% | Outperformed |
| 5 | Harrow Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Eyepoint Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Eyepoint Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Eyepoint Inc |
31.16 | 2.79 |
 Regeneron Pharmaceuticals Inc |
95,499.36 | 16,896.20 |
 Glaukos Corp |
13,732.99 | 578.35 |
 Tarsus Pharmaceuticals Inc |
3,184.51 | 682.20 |
 Viridian Therapeutics Inc |
2,912.01 | 70.90 |
 Ocular Therapeutix Inc |
1,483.56 | 52.05 |
| SUBTOTAL | 118,879.77 | 18,577.40 |
Sign in to see all competitors of Eyepoint Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Eyepoint Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Eyepoint Inc's Competitors Named by the Company
Competitive relationships identified from Eyepoint Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Reshape Lifesciences Inc | Company report | 85% |
| Lucentis | Company report | 85% |
| Avastin | Company report | 85% |
| Eylea | Company report | 85% |
| Allergan | Company report | 85% |
| Clearside Biomedical Inc | Company report | 85% |
| Lyra Therapeutics Inc | Company report | 85% |
| Glaukos Corp | Company report | 85% |
| Harrow Inc | Company report | 85% |
| Aerie Pharmaceuticals Inc | Company report | 85% |
| Outlook Therapeutics Inc | Company report | 85% |
| Oculis Holding Ag | Company report | 85% |
| Kiora Pharmaceuticals Inc | Company report | 85% |
| Alimera Sciences Inc | Company report | 85% |
| Tarsus Pharmaceuticals Inc | Company report | 85% |
| Ocular Therapeutix Inc | Company report | 85% |
| Viridian Therapeutics Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Eyepoint Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Eyepoint Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Glaukos Corp | Development and Commercialization of Ophthalmic Therapies 100.00 % |
| Tarsus Pharmaceuticals Inc | Reportable 100.00 % |
| Ocular Therapeutix Inc | Single Reportable Segment 100.00 % |
| Harrow Inc | Branded 79.40 % |
| Hyperion Defi inc | Digital Assets 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Eyepoint Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Eyepoint Inc | 31 | 13,028 | -1,432,911 |
| Regeneron Pharmaceuticals Inc | 95,499 | 1,096,444 | 312,615 |
| Glaukos Corp | 13,733 | 528,661 | -155,209 |
| Tarsus Pharmaceuticals Inc | 3,185 | 1,843,792 | -1,897,905 |
| Viridian Therapeutics Inc | 2,912 | 281,365 | -1,471,480 |
| Ocular Therapeutix Inc | 1,484 | 160,166 | -927,529 |
| PEERS TOTAL | 118,849 | 1,029,007 | 192,428 |
Eyepoint Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Glaukos Corp | US 82.85 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Eyepoint Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 28 companies in Eyepoint Inc's industry classification, broader than the peer set above. Market cap in millions of $.Eyepoint Inc ranks #21 of 28 companies by market capitalization in its industry, holding 0.01 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,513, indicating a moderately concentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Agilent Technologies inc | 49,457 | 22.37 % |
| 2 | Waters Corporation | 44,938 | 20.32 % |
| 3 | Mettler toledo International Inc | 34,729 | 15.71 % |
| 4 | Illumina Inc | 32,609 | 14.75 % |
| 5 | Revvity Inc | 1,234 | 5.2% |
| 6 | Avantor Inc | 1,234 | 5.2% |
| 7 | Bio rad Laboratories Inc | 1,234 | 5.2% |
| 8 | Bruker Corporation | 1,234 | 5.2% |
| 9 | 10x Genomics Inc | 1,234 | 5.2% |
| 10 | Alamar Biosciences Inc | 1,234 | 5.2% |
| 21 | Eyepoint Inc | 31 | 0.01 % |
Market cap and industry share for the rest of Eyepoint Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-06.
Eyepoint Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 16 | Quanterix Corporation | 137 | -43.33 % |
| 17 | Kewaunee Scientific Corporation | 100 | -17.34 % |
| 18 | Seer Inc | 91 | -24.42 % |
| 19 | Harvard Bioscience Inc | 38 | 39.77 % |
| 20 | Precipio inc | 1,234 | 12.3% |
| 21 | Eyepoint Inc | 31 | -97.23 % |
| 22 | Rapid Micro Biosystems Inc | 1,234 | 12.3% |
| 23 | Bionano Genomics Inc | 1,234 | 12.3% |
| 24 | Lifeloc Technologies Inc | 1,234 | 12.3% |
| 25 | Astrotech Corp | 1,234 | 12.3% |
| 26 | Scientific Industries Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Eyepoint Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-06. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Eyepoint Inc's Valuation vs Competitive Position
Valuation multiples vs the Laboratory Analytical Instruments industry average (49 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Laboratory Analytical Instruments industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 33.2x | - |
| EV / EBITDA | - | 20.6x | - |
| P/B | 5.1x | 2.9x | +2.2x |
| Return on Equity | -1.36 % | industry aggregate | -7.45 % |
| Return on Invested Capital | - | -10.58 % (avg) | - |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Eyepoint Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | -62.06 % | -57.84 % | 500.00 % | 69.10 % | 7.27 % | 11.14 % | -5.97 % | -27.50 % |
| Operating Margin | -885.78 % | -1,435.27 % | -235.02 % | -108.28 % | -149.64 % | - | - | - |
| Return on Invested Capital | -103.06 % | -20.55 % | -56.26 % | -46.97 % | -18.06 % | -27.68 % | -26.65 % | -42.81 % |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Eyepoint Inc's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Eyepoint Inc falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 4.2% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Eyepoint Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | Moderate | Industry HHI of 1,513 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | High (capital intensive) | Capital intensity (capex / revenue) of 142.79 % vs industry average 3.87 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Eyepoint Inc's dedicated Suppliers and Customers pages, not here.
Eyepoint Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Eyepoint Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Eyepoint Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 7.4 points below the industry aggregate.
- Latest-quarter revenue run-rate is decelerating (-27.3% annualized vs trailing 12 months).
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (41.70 %) show financial-distress signals, a possible opening to gain share.
Threats
- High capital intensity requires continuous reinvestment just to keep pace with the industry.
Methodology: see Methodology: SWOT Analysis.
Eyepoint Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Eyepoint Inc | 4.89 | 6.71 | - |
| Regeneron Pharmaceuticals Inc | 0.58 | 3.56 | 0.06 |
| Glaukos Corp | 1.12 | 4.90 | - |
| Tarsus Pharmaceuticals Inc | 0.50 | 3.03 | 0.25 |
| Viridian Therapeutics Inc | - | 14.05 | 0.13 |
| Ocular Therapeutix Inc | 11.92 | 12.79 | 0.14 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Eyepoint Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Eyepoint Inc | Q2 2026 | -90.5 % | - |
| Regeneron Pharmaceuticals Inc | Q3 2026 | +36.3 % | +33.5 % |
| Glaukos Corp | Q3 2026 | +59.0 % | - |
| Tarsus Pharmaceuticals Inc | Q3 2026 | +63.9 % | - |
| Viridian Therapeutics Inc | Q1 2026 | +95.8 % | - |
| Ocular Therapeutix Inc | Q2 2026 | +0.1 % | - |
| PEERS TOTAL | +36.6 % | -17.7 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Eyepoint Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Eyepoint Inc | Q2 2026 | - | -1.6 % |
| Regeneron Pharmaceuticals Inc | Q3 2026 | +104.1 % | +49.1 % |
| Glaukos Corp | Q3 2026 | +11.3 % | +27.2 % |
| Tarsus Pharmaceuticals Inc | Q3 2026 | +67.2 % | -36.5 % |
| Viridian Therapeutics Inc | Q1 2026 | - | -79.8 % |
| Ocular Therapeutix Inc | Q2 2026 | +3.4 % | +170.4 % |
Eyepoint Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Eyepoint Inc | - | - | - |
| Regeneron Pharmaceuticals Inc | 11.50% | 13.00% | 15.07% |
| Glaukos Corp | - | - | - |
| Tarsus Pharmaceuticals Inc | - | - | - |
| Viridian Therapeutics Inc | - | - | - |
| Ocular Therapeutix Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Eyepoint Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Eyepoint Inc | - | 11.17 |
| Regeneron Pharmaceuticals Inc | 20.00 | 5.65 |
| Glaukos Corp | - | 23.74 |
| Tarsus Pharmaceuticals Inc | - | 4.67 |
| Viridian Therapeutics Inc | - | 41.07 |
| Ocular Therapeutix Inc | - | 28.50 |
| PEERS AVERAGE | 37.54 | 6.40 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.